Iran war clouds India's FY27 growth forecast; S&P cuts to 6.6%
S&P Global has downgraded India's FY27 growth forecast to 6.6% due to the economic fallout from the Iran war, citing tightened fiscal space and elevated energy costs.
India's economic outlook has darkened as the Iran war keeps oil prices elevated, forcing the government to allocate more fiscal resources to energy subsidies. S&P Global's downgrade reflects the impact of crude costs on India's already-stretched budget, particularly for agriculture, fertilizers, and power generation.
Energy-intensive sectors like railways, fertilizer production, and thermal power generation face margin compression as feedstock costs rise. Food inflation is also ticking higher due to increased agricultural input costs. The fiscal hit comes at an awkward time: India's government is trying to invest in green energy infrastructure while managing near-term fiscal discipline.
The downgrade signals that even as the US and Iran negotiate a ceasefire, global energy prices are unlikely to normalize quickly. India's growth trajectory for FY27 now hinges on oil market stabilization and renewed manufacturing competitiveness. Delayed monetary easing by the RBI could also constrain consumption and investment growth. India's vulnerability to external energy shocks underscores the urgency of diversifying away from crude imports.
More from India
Radico resumes Gulf shipments as tensions ease
Indian liquor maker Radico Khaitan has resumed shipments to Gulf countries after pausing due to the Iran war. Easing tensions and peace hopes are allowing business operations to normalize.
Mamata says she won't resign: What happens next?
West Bengal Chief Minister Mamata Banerjee firmly stated she will not resign despite her party's major election defeat. The statement raises questions about constitutional processes for forming a new government.
Biocon's Kiran picks family member as successor
Biocon founder and CEO Kiran Mazumdar Shaw has named her niece Claire Mazumdar as her successor. The move signals a family-centered succession plan for India's major biotech firm.